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ABSTRACT  
Placental  ischemic  disease  and  adverse  pregnancy  outcomes  are  frequently  observed  
in   patients   with   antiphospholipid   syndrome   (APS).      Despite   the   administration   of  
conventional   antithrombotic   treatment   a   significant   number   of   women   continue   to  
experience   adverse   pregnancy   outcomes,   with   uncertain   prevention   and  
management.     Efforts   to  develop  effective  pharmacological  strategies   for   refractory  
obstetric  APS  cases  will  be  of  significant  clinical  benefit  for  both  mothers  and  fetuses.  
Although  the  antimalarial  drug,  hydroxychloroquine  (HCQ)  is  increasingly  used  to  treat  
pregnant  women  with  APS,  little  is  known  about    its  efficacy  and  mechanism  of  action  
of  HCQ.  
Because   complement   activation   plays   a   crucial   and   causative   role   in   placental  
ischemia  and  abnormal   fetal  brain  development   in  APS  we  hypothesised  that  HCQ  
prevents  these  pregnancy  complications  through  inhibition  of  complement  activation.  
Using  a  mouse  model  of  obstetric  APS  that  closely  resembles  the  clinical  condition,  
we   found   that   HCQ   prevented   fetal   death   and   the   placental   metabolic   changes   -­
measured   by   proton   magnetic   resonance   spectroscopy   in   APS-­mice.   Using   111In  
labelled  antiphospholipid  antibodies  (aPL)  we  identified  the  placenta  and  the  fetal  brain  
as  the  main  organ  targets  in  APS-­mice.  Using  this  same  method,  we  found  that  HCQ  
does   not   inhibit   aPL   binding   to   tissues   as   was   previously   suggested   from   in   vitro  
studies.  While  HCQ  did  not  affect  aPL  binding  to   fetal  brain   it  prevented  fetal  brain  
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abnormal  cortical  development.  HCQ  prevented  complement  activation  in  vivo  and  in  
vitro.  Complement  C5a   levels   in   serum  samples   from  APS  patients  and  APS-­mice  
were  lower  after  treatment  with  HCQ  while  the  antibodies  titres  remained  unchanged.    
HCQ  prevented  not  only  placental  insufficiency  but  also  abnormal  fetal  brain  
development  in  APS.  By  inhibiting  complement  activation,  HCQ  might  also  be  an  
effective  antithrombotic  therapy.  
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The  antiphospholipid  syndrome  (APS)   is  an  autoimmune  disease  associated  
with   the   presence   of   antiphospholipid   autoantibodies   (aPL).   APS   occurs   most  
commonly   in   young   women   of   reproductive   age   and   is   characterised   by   adverse  
pregnancy  outcomes  frequently  associated  with  placental  pathologies  [1-­4].    
There   is   growing   evidence   for   transplacental   passage   of   aPL,   and   brain  
abnormalities  and  cognitive  impairment  has  been  described  in  infants  born  to  mothers  
affected   by   APS,   suggesting   that   exposure   to   aPL   in   utero   can   affect   fetal   brain  
development  and  thus  might  induce  behavioural  and  cognitive  problems  later  in  life  [5-­
7].  Abnormal  behaviour  in  the  offspring  of  APS-­mice  has  also  been  described  [8,  9].  
Thus,  the  impact  of  maternal  aPL  antibodies  on  the  offspring  may  extend  beyond  the  
known  association  with  adverse  pregnancy  outcome.  
aPL  constitute  a  heterogeneous  group  of  autoantibodies  with  different  
specificities  and  different  target  organs’  principally  the  female  reproductive  system  
and  the  vascular  system.  β2-­glycoprotein  I  (β2GPI)  is  the  major  antigen  for  clinically  
relevant  antibodies  in  APS  [4].  In  vitro  studies  demonstrated  that  aβ2GPI  antibodies  
isolated  from  patients  avidly  bind  to  trophoblast  monolayers  isolated  from  human  
placentas  [10,  11]  and  to  isolated  mouse  fetal  cortical  neurons  [9].  Furthermore,  
some  of  these  in  vitro  studies  demonstrated  that  aβ2GPI  affect  trophoblast  function  
and  invasion  [12,  13]  and  mouse  fetal  cortical  neurons  cytoarchitecture  [9].  Ex-­vivo  
studies  also  showed  robust  aPL  deposition  in  placentas  in  mice  and  humans  [9,  14,  
15].  However,  no  data  are  available  on  the  binding  of  aβ2GPI  antibodies  and  the  
identification  of  the  target  organs  in  vivo.    
Pregnancy  complications  in  APS  have  been  attributed  to  placental  thrombosis  
and   infarcts   and   management   of   obstetric   APS   is   based   on   attenuating   the  
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procoagulant   state.   However,   in   many   cases   there   is   no   evidence   of   decidual  
thrombosis  or  placental  vasculopathy,  and  instead  inflammatory  signs  are  present  [16-­
18].        Treatment  with  aspirin  and  heparin  has  become  a  conventional  option  for  women  
with  obstetric  APS.  While  the  use  of  aspirin  and  heparin  has  improved  the  pregnancy  
outcome   in   obstetric   APS,   current   treatment   fails   in   a   significant   number   of  
pregnancies   [19,   20]   raising   the   need   to   explore   other   treatments   to   improve  
obstetrical  outcome.  
Hydroxychloroquine   is   a  medication   originally   used   to   prevent/treat  malaria.  
This  antimalarial  drug  has  also  been  used  to  treat  pregnant  women  with  APS  for  many  
years.  While  recent  studies  suggest  that  HCQ  might  improve  pregnancy  outcomes  in  
APS  [21],  the  use  of  HCQ  is  still  controversial;;  most  of  the  beneficial  effects  of  HCQ  in  
pregnancy  constitute  anecdotal  evidence  and  little  is  known  about  its  mechanism  of  
action  [22-­24].    
Here  we  evaluate  the  effects  of  HCQ  in  the  mother  and  developing  fetus  in  a  
mouse  model  of  obstetric  APS.  Knowing  that  complement  activation  plays  a  crucial  
role  in  the  pathogenesis  of  adverse  pregnancy  and  fetal  outcomes  in  APS  in  mice  and  
women  [9,  14,  17,  25-­27],  we  hypothesised  that  HCQ  protects  pregnancy  in  APS  by  
inhibiting  complement  activation.    
  
METHODS  
Purification  of  aPL  antibodies  
antiβ2GPI  antibodies  were  isolated  from  7  patients  with  primary  APS  (PAPS).  
Autoantibody  profiles  and  clinical  features  from  patients  (untreated  and  treated  with  
HCQ)  are  described  in  Table  1.  All  patients  met  Sidney  Laboratory  criteria  for  APS  
[28].    The  patients  were  identified  through  the  Registry  of  Connective  tissue  diseases  
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(10/H0405/35)  at  St  Thomas’  Hospital.  The  NHS  National  Research  Ethics  Service  
approved  the  collection  and  utilization  of  samples  for  research  purposes.    
IgG  from  APS  patients  and  from  healthy  non-­autoimmune  individuals  was  
purified  using  protein  G  sepharose  chromatography  [17].  A  further  affinity  purification  
step  using  peptides  mimetic  to  regions  of  β2GPI  immobilised  onto  magnetic  beads  
was  performed  in  the  IgG  fractions  from  patients  with  APS  in  order  to  obtain  purified  
aβ2GPI  antibodies  [29].  Blank  et  al.  demonstrated  that  these  peptides  –  that  
correspond  to  three  epitopes  located  in  domains  I-­II,III  and  IV  of  the  β2GPI  molecule-­  
bind  to  human  anti-­β2GPI  Abs  and  prevent  fetal  loss  and  endothelial  activation  in  
experimental  APS  [29].  Functionality  of  the  isolated  aβ2GPI  antibodies  was  
confirmed  by  ELISA.    Endotoxin  removal  in  each  sample  was  performed  using  high  
capacity  endotoxin  removal  spin  columns  (Pierce  Thermoscientific).  All  samples  
showed  to  be  endotoxin  free  (<  0.01  ng/mL)  using  the  LAL  Chromogenic  Endotoxin  
Quantitation  Kit.      
  
Animals  
All  housing  and  experimental  procedures  were  performed  in  compliance  with  
the  UK  Home  Office  Animals  Scientific  Procedures  Act  1986  (Home  Office  project  
licence  number  60/4305).  C57BL/6  mice  (2-­3  months  old)  purchased  from  
commercial  vendors  were  used  in  all  experiments.  A  group  of  females  were  mated  
with  previously  isolated  males.  The  presence  of  a  vaginal  plug  defined  day  0  of  
pregnancy.  
  
Mouse  model  of  obstetric  APS  (APS-­mice)  
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Affinity  purified  antibodies  to  β2GPI  isolated  from  patients  and  normal  human  
IgG  (NHIgG)  (control  antibodies)  were  administered  intravenously  by  a  bolus  
injection  (100  µg/mouse)  on  day  7  of  pregnancy  followed  by  maintenance  doses  
through  a  microosmotic  pump  (  Alzet,  model  1002,  pumping  rate  0.25  µl/h,  reservoir  
volume  100  µl).  This  model  uses  similar  amounts  of  aPL  antibodies  to  the  passive  
transfer  model  considering  that  in  the    passive  transfer  model  the  whole  IgG  fraction  
from  patients  with  APS  are  injected  intraperitoneally  [17].  Administration  through  
microosmotic  pumps  ensures  constant  antibody  concentrations  are  maintained  
throughout  pregnancy  to  closely  resemble  the  clinical  condition.  A  group  of  pregnant  
mice  received  hydroxychloroquine  (HCQ,  dissolved  in  sterile  distilled  water)  
administered  by  a  second  microosmotic  pump  (Alzet  model  1002)  inserted  on  day  8  
of  pregnancy.  Based  on  clinical  treatment  regimes,  in  which  the  recommended  
dosage  is  6.5  mg/kg/day,  we  studied  the  effects  of  200  µg  HCQ/mouse/day.    
  
Single  photon  emission  computed  tomography  (SPECT/CT)  imaging  of  aβ2GPI  
biodistribution  in  vivo  
  
Preparation  of  111In-­labelled  antibodies.  
Antibodies  to  β2GPI  and  control  antibody  NHIgG  were  conjugated  with  the  
bifunctional  chelator  p-­SCN-­Bn-­CHX-­A”-­DTPA  -­using  the  same  chelator/antibody  
ratio-­ as  described  previously  [30].  The  immunoconjugates  were  then  isolated  in  
ammonium  acetate  solution  (0.2  M,  pH  6)  by  purification  with  size  exclusion  columns  
and  radiolabelled  with  an  equal  volume  of  111InCl3  (Mallinckrodt  Medical  B.V.,  Petten,  
Netherlands).  The  radiolabelled  conjugates  were  isolated  using  an  a  HPLC  BioSep  
SEC  s2000  size  exclusion  column  (Phenomenex,  Macclesfield,  UK)  (isocratic  mobile  
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phase,  PBS  containing  2  mM  EDTA,  1  ml/min,  UV  detector:  λ  =  280  nm).  
Radiochemical  yield  and  purity  was  >  97%.  Day  13  pregnant  and  non-­pregnant  mice  
were  injected  intravenously  were  injected  intravenously  with  15-­35  MBq  111In-­aβ2GPI  
antibodies  (80  µL,  0.56  mg  mL-­1,  45  µg  of  immunoconjugate)  and  scanned  48  h  later  
(predetermined  maximal  binding)  at  gestational  day  15.  Images  to  visualize  IgG  
binding  to  different  target  organs  were  captured  under  anaesthesia  using  a  
NanoSPECT/CT  Silver  Upgrade  preclinical  scanner  (Mediso  Ltd.,  Budapest,  
Hungary).  After  whole  body  imaging  the  mice  were  killed  and  organ/tissues  were  
dissected  and  frozen.  The  net  counts  per  minute  (CPM)  for  each  tissue  and  standard  
were  determined  using  a  Wallac  1282  Compugamma  Universal  Gamma  Counter.  
The  percent  injected  radioactivity  dose  (%ID)  was  determined  from  CPM  in  the  
tissue  calibrated  against  a  sample  counted  in  the  dose  calibrator  used  to  measure  
the  injected  dose.  The  content  of  radiolabelled  IgG  in  each  tissue  was  expressed  as  
ng  IgG  per  gram  of  tissue  calculated  from  the  %ID/g  and  the  specific  activity  of  the  
labelled  antibody.      
  
Proton  Magnetic  resonance  spectroscopy  studies  (1HMRS)  
This  non-­invasive  in  vivo  imaging  modality  was  used  to  study  the  biochemical  
and  metabolic  profile  in  placentas  and  fetal  brains  in  APS-­mice  and  respective  
controls  treated  with  NHIgG.  All  MRI  experiments  were  performed  using  a  7-­Tesla  
horizontal  bore  NMR  spectrometer  (Agilent,  Yarnton,  UK),  equipped  with  high-­
performance  gradient  insert  (12  cm  inner  diameter),  maximum  gradient  strength  400  
mT/m).  At  day  15  of  pregnancy,  APS  and  control  mice  were  anaesthetized  with  1.8%  
isofluorane  in  oxygen/air  (50/50,1L/min)  and  placed  in  a  cradle  (Rapid  Biomedical  
GmbH,  Rimpar,  Germany).  Spectra  were  analyzed  using  LCModel  (http://s-­
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provencher.com/pages/lcmodel.shtml.  The  1H-­MRS  signal  from  creatine  (Cr)  
(measure  of  the  global  brain  function  or  integrity)  was  used  to  normalize  the  signals  
from  other  metabolites  measured  within  the  same  voxel.  
  
Immunofluorescence  studies    
Frozen  sections  from  placentas  and  fetal  brains  from  control  mice  were  
stained  with  antibodies  to  β2GPI  (Santa  Cruz,  apoH  antibody  (M-­190):sc366275,  
dilution  1/400)  followed  by  FITC-­conjugated  anti  rabbit  IgG  (Sigma-­Aldrich  F9887,  
dilution  1/400)  to  investigate  the  presence  of  the  protein  in  these  tissues.  Frozen  
sections  from  placentas  and  fetal  brains  from  mice  treated  with  aβ2GPI  and  aβ2GPI  
+HCQ-­treated  mice  were  stained  for  aβ2GPI  deposition  using  a  Texas  Red-­
conjugated  anti  human  IgG  antibody  (Thermo  Scientific,  PA1-­28834,  dilution  1/500).  
Texas  Red-­conjugated  anti  human  IgG  antibody  was  also  used  to  visualize  NHIgG  in  
placenta  and  fetal  brain  in  NHIgG-­treated  mice.  Antibodies  to  microtubule  associated  
protein-­2  (MAP-­2;;  Sigma-­Aldrich  M3696,  dilution  1/100)  -­  a  marker  of  intact  neuronal  
cell  bodies  -­  and  neurofilament  200  (NF-­200;;  Sigma  Aldrich  N4142,  dilution  1/400)  –  
marker  of  dendritic  and  axons  structure-­  were  used  to  investigate  neurons  
cytoarchitecture  [9].  Bound  antibodies  were  detected  using  a  FITC-­conjugated  anti  
rabbit  IgG  (Sigma-­Aldrich  F9887,  dilution  1/400).  Frozen  sections  of  placentas  and  
fetal  brains  were  stained  for  complement  deposition,  using  monoclonal  anti-­C3b,  
iC3b,  C3c  antibodies  (clone  2/11,  Hycult  Biotech,  dilution  1/50)  followed  by  a  FITC-­
conjugated  anti-­rat  IgG  (Sigma-­Aldrich  F6258,  dilution  1/400).  Diamidino-­2-­
phenylindole  (DAPI,  Thermo  Fisher  Scientific,  62248)  was  used  for  nuclear  
counterstains  in  all  immunofluorescence  studies.  
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Production  of  superoxide  anion  in  placentas  was  measured  using  
dihydroethidium  (DHE,  Sigma-­Aldrich  37291).  
  
ELISA  to  evaluate  the  effect  of  HCQ  on  antibody  complement  fixing  and  
activating  capacity    
Complement  fixing  capacity  was  measured  by  an  ELISA  that  uses  mouse  aPL  
antibodies  (FB1,  mouse  IgG2b)  which  have  been  shown  to  activate  complement  in  
different  mouse  models  [31,  32].  Non-­fixing  antibody  FD1  was  used  as  control  [32].  
Polystyrene  plates  were  coated  with  β2GPI  and  cardiolipin.  FB1  or  control  antibody  
FD1(100  µg/ml)  were  incubated  onto  the  polystyrene  plates.  After  washing  with  
PBS/tween,  a  source  of  complement  (normal  mouse  serum,  dilution  1/100)  was  
added  to  the  wells  with  and  without  increasing  concentrations  of  HCQ  (20-­50  and  
100  ng/ml).  HCQ  concentrations  were  calculated  based  on  the  clinical  recommended  
dose  (6.5  mg/kg)  and  blood  volume  of  distribution  of  116  L/kg  [33].  Plates  were  
incubated  30  min  at  37°C  under  continuous  shaking.  The  wells  were  aspirated  and  
stored  at  -­°20C  for  the  determination  of  complement  C3  split  product  C3adesArg  by  
ELISA  and  washed.    
To  study  C1q  binding,  antimouse  C1q-­HRP  was  added  and  incubated  for  1h  
RT,  then  washed  as  described  before.  To  study  C3  activation,  monoclonal  rat  
antibody  anti  mouse  C3b/iC3b/C3d  (Hycult,  USA)  was  added  and  incubated  for  1  h  
RT,  then  washed  as  described  before.  Secondary  antibody  (anti-­rat  IgG  H&L-­HRP)  
was  added  and  incubated  for  1h  at  RT,  then  washed  as  above.    HRP  was  developed  
using  prewarmed  substrate  (TMB).  Assays  were  performed  in  duplicate  and  read  at  
450nm.  Background  was  assessed  as  the  binding  to  wells  without  any  
β2GPI/cardiolipin  added  and  was  subtracted  from  the  coated  plates.  Other  controls  
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consisted  of  mouse  serum  from  C3  deficient  mice  and  C1q  deficient  mice  instead  of  
fresh  mouse  serum.  
  
Measurement  of  C3a  and  C5a  
The  C3adesArg  and  C5adesArg  in  serum  and  wells  contents  from  the  
complement  fixing  capacity  ELISA  were  measured  by  sandwich  enzyme-­linked  
immunosorbent  assay  (ELISA)  as  previously  described  [34].    
  
Statistical  analysis  
Data  are  expressed  as  mean  ±  SD.  Statistical  differences  between  groups  
were  determined  using  one-­way  ANOVA  with  subsequent  two-­tailed  Student  t  test.  
  
RESULTS    
HCQ  prevented  fetal  death  and  placental  abnormalities  in  APS  
Continuous  exposure  to  aPL  antibodies  through  microosmotic  pump  increased  the  
fetal  resorption  frequency  compared  to  the  passive  transfer  model  in  which  
antibodies  are  given  in  two  single  injections  [17].  In  the  new  APS-­model  more  than  
50%  of  the  embryos  did  not  survive  (Figure  1A,  Table  2).  The  surviving  fetuses  were  
growth  restricted  and  placentas  were  smaller  compared  to  control  NHIgG-­treated  
mice  (Table  2).  Increased  production  of  superoxide  anion  –indicative  of  increased  
oxidative  stress  was  observed  in  placentas  from  aβ2GPI  –treated  mice  (Figure  1B).  
Administration  of  HCQ  to  APS-­mice  prevented  fetal  death,  increased  placental  and  
fetal  weight  and  decreased  placental  superoxide  production  (Table  2,  Figure  1A).  
HCQ-­treated  mice  showed  normal  pregnancy  outcomes,  comparable  to  NHIgG-­
treated  mice  (Table  2).  
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1HMRS  was  used  to  assess  the  metabolic  profile  of  placentas  in  vivo  in  utero  at  day  
15  of  pregnancy.    The  1H-­MRS  signal  from  creatine  (measure  of  the  global  brain  and  
placental  function  or  integrity)  was  used  to  normalize  the  signals  from  other  
metabolites  measured  within  the  same  voxel.  A  significant  decrease  in  chemical  
mediators  glucose  (Glc/Cr),  lactate  (Lac/Cr)  and  choline  derivates  (GPC/Cr  and  
PCh/Cr)  -­  involved  in  energy  metabolism,  membrane  lipid  function  and  
neuroprotection  –  was  observed  in  placentas  from  APS-­mice  compared  to  NHIgG-­
treated  mice  (Table  3).  HCQ  prevented  these  placental  metabolic  abnormalities  in  
APS-­mice  (Table  3)  
  
HCQ  protects  fetal  brain  development  
Diminished  NF200  (marker  of  dendritic  and  axons  structures)  and  MAP-­2  
(marker  intact  neuronal  cell  bodies)  staining  -­  indicative  of  abnormal  neuronal  
cytoarchitecture  -­  was  observed  in  the  fetal  brains  in  APS-­mice  compared  to  NHIgG-­  
treated  mice  ([9],  Figure  1C).  HCQ  prevented  aPL-­induced  abnormal  fetal  cortical  
brain  development  (Figure  1C).  Similar  to  what  was  observed  in  the  placenta,  a  
significant  decrease  in  Glc/Cr,  Lac/Cr,  GPC/Cr  and  PCh/Cr  was  also  detected  in  fetal  
brains  from  APS-­mice  (Table  3).  HCQ  prevented  these  metabolic  abnormalities  in  
fetal  brains  in  APS-­mice.  
  
aPL  binding  in  vivo  -­  SPECT/CT  studies  
aβ2GPI  antibodies  and  NHIgG  were  labelled  with  111In  and  visualized  in  vivo  
using  SPECT/CT  in  pregnant  and  non-­pregnant  mice  (see  videos  in  Suppl  Material).    
In  the  pregnant  mouse  111In  -­aβ2GPI  were  rapidly  cleared  from  the  circulation  and  
deposited  in  the  fetal  sacs  (Figure  2B  left,  2B1).  Within  the  fetal  sacs  111In  -­aβ2GPI  
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antibodies  were  detected  in  placentas  and  fetal  brains  by  ex-­vivo  gamma  counting  
(Table  4).    In  contrast  to  pathogenic  aβ2GPI,  a  large  amount  of  the  injected  dose  of  
111In-­NHIgG  remained  in  circulation  at  48  hours  (Table  4).  SPECT/CT  studies  
showed  the  presence  of    111In-­NHIgG  in  the  placenta  but  not  in  the  fetus  (Figure  2B  
right,  2B2)  .  Ex-­vivo  gamma  counting,  showed  minimal  amount  of  111In-­NHIgG  in  the  
fetal  brains  (Table  4).    In  the  non-­pregnant  mouse  111In-­aβ2GPI  and  111In-­NHIgG  
remained  longer  in  circulation  compared  to  pregnant  mice  (Figure  2A,  Table  4).    
aβ2GPI  antibodies  were  found  in  the  spleen  and  liver  of  the  non  pregnant  mouse  
(Figure  2A  left).    
Immunohistochemical  studies  confirmed  the  presence  of  aβ2GPI  antibodies  in  
the  placenta  (Figure  3A)  and  fetal  cortical  brain  detected  by  SPECT/CT  and  ex-­vivo  
gamma  counting  (Figure  3B).    In  accordance  with  the  ex-­vivo  gamma  counting  
studies,  NHIgG  deposition  was  found  in  the  placenta  but  not  in  the  fetal  brain  (Figure  
3C  and  D).  
Staining  for  β2GPI  in  placentas  and  fetal  brains  showed  abundant  expression  
of  the  protein  (Figure  3E  and  3F)  that  might  explain  the  tropism  of  aβ2GPI  for  these  
organs.  
  
HCQ  does  not  affect  aPL  binding  to  placenta  and  fetal  brain  in  pregnant  mice    
Because  a  recent  in  vitro  study  suggested  that  HCQ  reduces  the  binding  of  aPL  
antibodies  to  the  syncytiotrophoblast  [35,  36],  we  investigated  if  this  mechanism  
could  account  for  the  protective  effects  of  HCQ  we  observed  in  obstetric  APS  in  mice  
in  vivo.  
Ex-­vivo  gamma  counting  in  pregnant  mice  demonstrated  that  the  administration  of  
HCQ  does  not  affect  the  binding  of  111In-­aβ2GPI  to  placentas  and  fetal  brain  (Table  
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4).  The  biodistribution  of  aβ2GPI  in  pregnant  mice  treated  with  or  without  HCQ  was  
identical,  the  placentas  and  fetal  brains  the  main  target  sites  (Table  4).  
Immunohistochemical  studies  in  placentas  and  fetal  brain  confirmed  the  SPECT/CT  
and  ex-­vivo  gamma  counting  observations  (Figure  4A).  Staining  for  aβ2GP  
antibodies  in  aβ2GP+HCQ-­treated  mice  was  not  different  from  mice  treated  with  
aβ2GP  alone  (Figure  4A).    
  
HCQ  inhibits  antibody  complement  fixing  and  activating  capacity  in  vitro  
To  investigate  the  effects  of  HCQ  on  antibody  complement  fixation  and  activation  
capacity  we  used  an  ELISA  method.  Addition  of  HCQ  inhibited  the  binding  of  C1q  to  
mouse  complement  fixing  antibody  FB1  and  also  prevented  generation  of  
complement  split  products  C3a  and  C3b/iC3b/C3d  (Table  5).  A  dose  response  effect  
was  observed  with  total  inhibition  at  a  concentration  of  HCQ  of  100  ng/ml  (Table  5).  
When  serum  from  mice  injected  with  HCQ  was  used  as  a  source  of  complement,  
complement  C1q  fixing  capacity  and  C3  activation  was  also  abolished  (Table  5).  
  
HCQ  inhibits  complement  activation  in  vivo  
Mouse  studies  
Increased  complement  deposition  that  was  previously  described  in  placentas  and  
fetal  brains  in  the  mouse  model  of  APS  were  not  observed  when  mice  received  HQC  
([9],  Figure  4B).  In  addition,  complement  split  products  C3a  and  C5a  levels  
decreased  dramatically  in  aβ2GPI  treated  with  HCQ,  compared  to  mice  that  received  





To  investigate  if  complement  inhibition  occurs  after  treatment  with  HCQ  in  humans,  
we  measured  complement  activation  product  C5adesArg  levels  and  antibody  titres  in  
serum  from  APS  patients  before  and  after  treatment  with  HCQ  (6.5  mg/kg,  >6  
months  after  starting  the  treatment).  C5adesArg  levels  diminished  after  treatment  
with  HCQ  while  the  aCL  and  aβ2GPI  titres  remained  unchanged  (Table  7).  
  
DISCUSSION  
Placental-­mediated  pregnancy  complications  are  frequently  associated  with  
antiphospholipid  antibodies.  While  several  in  vitro  studies  demonstrated  binding  of  
aPL  antibodies  to  trophoblast  cell  lines  and  primary  human  trophoblasts  [10-­13]  and  
fetal  cortical  neurons  in  vitro  [9]  it  is  still  unclear  if  this  happens  in  vivo  and  what  
pathogenic  mechanisms  play  a  role.  Here  we  found  evidence  that  aPL  antibodies  
bind  to  the  placenta  and  fetal  brain  in  vivo.  Using  in  vivo  SPECT/CT  we  found  that  
aβ2GPI  antibodies  are  rapidly  cleared  from  circulation  and  large  amounts  of  the  
radiolabelled  antibody  are  entrapped  in  the  placentas  and  fetal  brains  within  the  
fetuses  in  the  fetal  sacs.    To  our  knowledge  this  is  the  first  study  to  show  in  vivo  
binding  of  antibodies  to  the  placenta  and  the  developing  fetal  brain.    This  study  
demonstrates  that  pathogenic  antibodies  to  β2GPI  are  capable  of  crossing  the  
placenta,  the  blood  brain  barrier  (BBB)  and  binding  to  the  fetal  brain.  Direct  binding  
of  aPL  antibodies  to  the  developing  brain  might  explain  the  abnormal  fetal  brain  
development  and  abnormal  behaviour  that  we  and  others  reported  in  the  offspring  of  
APS-­mice  [8,  9].    In  humans,  a  prospective  multicentre  registry  of  a  cohort  of  children  
born  to  mothers  with  APS  showed  presence  of  neurodevelopmental  abnormalities  
[6].  The  placenta  was  also  a  hot  spot  in  mice  injected  with  radiolabelled  NHIgG,  this  
can  be  explained  by  the  abundant  expression  of  the  neonatal  FcRn  receptor  that  
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facilitates  the  transfer  across  the  placenta  of  normal  IgG  [37].    
Despite  the  lack  of  knowledge  about  its  efficacy  and  mechanism  of  action,  
HCQ  has  been  used  to  treat  pregnant  women  with  APS  for  many  years  now  [21-­24].  
HCQ  protected  pregnancies  in  the  mouse  model  of  APS;;  fetuses  survived  and  
normal  placental  and  fetal  brain  development  was  observed  in  APS-­mice  treated  
with  HCQ.  In  addition,  HCQ  prevented  the  metabolic  abnormalities  observed  in  the  
placenta  and  fetal  brains  in  APS-­mice.  Despite  the  known  associations  between  
placental  dysfunction  and  fetal  brain  development,  there  are  few  available  tools  to  
evaluate  in  vivo  the  placental  metabolism  and  function  during  pregnancy.  In  this  
study,  we  used  1HMRS  as  an  important  tool  to  determine  in  vivo  metabolism  [38].  
This  non  invasive  methodology  might  have  significant  potential  clinical  implications,  
such  as  the  opportunity  to  identify  APS  patients  at  risk  of  placental  and  fetal  brain  
abnormalities  and  the  use  of  preventive  therapy.  Deficiency  in  chemical  mediators  
involved  in  energy  metabolism,  membrane  lipid  function  and  neuroprotection  were  
found  in  placentas  and  fetal  brains  in  APS-­mice.  HCQ  reversed  these  abnormal  
metabolic  profiles.  Oxidative  stress  affects  placental  metabolism  and  transport  of  
metabolites  to  the  fetus  [39,  40].  Increased  reactive  oxygen  species  production  
induced  by  aβ2GPI  antibodies  in  placentas  from  APS-­mice,  can  affect  placental  
metabolism  and  transport  of  nutrients  to  the  fetus  contributing  to  abnormal  fetal  brain  
development.  Because  low  levels  of  choline  have  also  been  associated  with  
abnormal  trophoblast  function  [41]  and  choline  is  a  neuroprotectant  [42],  we  can  
speculate  that  deficiency  of  choline  not  only  affects  placental  function  but  might  also  
exacerbate  the  direct  neurotoxic  effects  of  aβ2GPI  antibodies.    
While  the  use  of  HCQ  appears  to  be  safe  in  women  little  is  known  about  its  
mechanism  of  action  [43-­45].  While  some  in  vitro  studies  suggested  that  HCQ  
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inhibits  aPL  binding  to  trophoblasts  restoring  their  function  [35,  36],  our  ex  vivo  
gamma  counting  and  immunohistochemical  studies  demonstrated  that  HCQ  at  a  
dose  similar  to  the  therapeutic  dose  in  human,  does  not  affect  the  binding  of  aPL  to  
either  the  placenta  or  the  fetal  brain.    
An  association  between  complement  activation  and  placental  insufficiency  and  
abnormal  fetal  brain  development  was  observed  in  mice  treated  with  aβ2GPI  
antibodies.  We  previously  demonstrated  using  MRI  that  complement  deposition  is  
observed  in  fetal  brain  and  placenta  in  APS  mice  and  this  predicts  adverse  outcomes  
[9].  HCQ  was  shown  to  inhibit  complement  activation  in  vivo  and  in  vitro.  The  in  vitro  
studies  suggest  that  HCQ  inhibits  complement  activation  by  inhibiting  the  binding  of  
C1q,  the  first  step  in  the  activation  of  the  classical  pathway.  By  inhibiting  C1q  
binding,  HCQ  also  inhibits  the  generation  of  the  C3  convertase  and  cleavage  of  C3.  
Our  studies  do  not  rule  out  that  HCQ  might  also  inhibit  complement  activation  by  
other  pathways  downstream  of  C3.  That  HCQ  inhibits  complement  activation  
explains  why  while  aPL  antibodies  are  found  in  placenta  and  fetal  brain  in  APS-­mice  
treated  with  HCQ,  no  pathogenic  effects  were  observed  in  these  tissues.  Decreased  
plasma  complement  split  product  levels  and  diminished  C3b  deposition  were  
observed  in  placentas  and  fetal  brains  in  APS-­mice  treated  with  HCQ  and  this  was  
associated  with  improvement  in  placental  metabolism,  diminution  of  oxidative  stress  
and  prevention  of  abnormal  neurodevelopment.    These  data  suggest  that  
complement  inhibition  contributes  to  the  protective  effects  of  HCQ  on  fetal  brain  and  
placenta  in  obstetric  APS.    
Inflammation  is  thought  to  play  a  crucial  role  in  the  pathogenesis  of  APS  [46,  
17].  It  has  been  reported  that  HCQ  decreases  leukocyte  activation  and  reduces  
cytokine  and  reactive  oxygen  species  production  [47,  48].  Knowing  that  C5a  is  a  
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potent  activator  of  inflammatory  cells,  it  is  tempting  to  speculate  that  the  effects  of  
HCQ  in  reducing  inflammatory  cells  activation  can  be  mediated  by  complement  
inhibition.    Studies  using  human  samples  confirmed  our  observations  in  APS-­mice.  
Diminished  levels  of  C5a  were  observed  in  patients  after  treatment  with  HCQ.    
It  has  been  described  that  IgG  purified  from  patients  with  obstetric  APS  
inhibits  trophoblast  invasion  in  vitro  in  a  TLR4-­dependent  manner  [49]  and  that  HCQ  
decreases  TLR4  mRNA  in  BeWo’s  cells  restoring  trophoblast  invasion  [50].  Because  
C5a  can  modulate  TLR  signalling  through  a  receptor-­mediated  mechanism  [51],  it  is  
possible  that  downregulation  of  TLR4  might  act  synergistically  with  complement  
inhibition  in  the  protective  effects  of  HCQ  in  aβ2GPI-­induced  pregnancy  morbidity.  
Our  studies  suggest  that  HCQ  is  an  effective  therapy  not  only  to  prevent  fetal  
death  and  placental  insufficiency  but  also  to  protect  the  fetal  brain  in  APS.    
Excess  complement  generation  has  been  associated  with  significant  
thrombophilia  in  numerous  pathologies  including  APS  [52].  That  HCQ  inhibits  
complement  activation  might  also  explain  the  beneficial  effects  of  this  drug  to  prevent  
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LA   diagnostic   Clinical  features   Obstetric    
APS  





Pt  2   M/62   +   +   +   PAPS   DVT,  stroke     
Pt  3   F/48   +   +   +   PAPS   DVT,  PE   Preeclampsia  
  
Pt  4   F/38   +   +   +   PAPS   DVT   RM  
preeclampsia  




Pt  6   F/54   +   +   +   PAPS   DVT   RM,  preterm  
birth,  stillbirth  
Pt  7   F/45   +   +   +   PAPS      RM,  
preeclampsia  
Pt  8   F/38   +   +   +   PAPS      RM  
Stillbirth  
  
Pt  9   F/31   +   +   +   PAPS   DVT   RM  
IUGR  
Pt  10   F/34   +   +   +   PAPS      Preeclampsia  
HELLP  
syndrome  
Pt  11   F/32   +   +   +   PAPS      RM  
preeclampsia  















   FRF(%)   Placenta  (mg)   Fetus  (mg)  
NHIgG   10.4±5.9   122±9.9   401.5±22.8  
APS   54.2±11.1*   87.5±9.6*   302.1±18.5*  
APS  +HCQ   11.0±5.7   115.8±11.3   385.1±21.5  

























































































   Pregnant     Non  pregnant  
In111-­conjugated  IgG  








aβ2GPI   NHIgG  
Blood   89±27*   98±22*   304±42   261±110#   178±103#  
Placenta   500±245   490±154   615±312        
Fetal  brain   397±71*   427±60*   113±98        
Spleen   273±56   285±90   226±54   809±180#   572±167#  
















   OD  λ450  nm  x  100   C3adesArg  
(ng/ml)  
C1q  binding   C3b/iC3b/C3c  
FD1  (control)   65±08   17±5   97±23  
FB1  (complement  activating  
antibody)  
568±47*#   102±12*#   892±54*#  
FB1+  HCQ20   392±67*#   81±9*   556±28*#  
FB1+HCQ50   197±45*#   38±11*#   235±45*#  
FB1+HCQ100   57±12#   15±8#   86±19#  
FB1+serum  from  HCQ-­treated  
mouse  





   C3a  (ng/ml)   C5a  (ng/ml)  
NHIgG   43±7   21±5  
APS   156±34*   142±31*  
APS  +  HCQ   57±21   35±11  




































IgG   IgG  
Patient  8   65   68   132   72   72   45  
Patient    9   78   86   156   83   91   65  
Patient  10   124   132   97   130   128   22  
Patient  11   85   42   123   76   51   31  
Patient  12   135   56   198   145   67   39  





TABLE  AND  FIGURE  LEGENDS  
Table  1.  Clinical  and  laboratory  features  of  the  patients  used  as  a  source  of  human  
aβ2GPI  antibodies  (Pt1  -­  Pt7)  and  patients  that  received  HCQ  treatment  (Pt  8  -­  Pt12).  
Pt  indicates  patient.  All  patients  met  Sidney  Laboratory  criteria  for  APS  [28].  ACA=  
anticardiolipin,  β2=β2gycoprotein  I  (β2GPI),  RM=recurrent  miscarriages,  APS=  
primary  antiphospholipid  syndrome,  DVT=deep  vein  thrombosis,  PE=  pulmonary  
embolism.  
  
Table  2.  Pregnancy  outcomes  in  mice  treated  with  NHIgG,  APS-­mice,  APS-­mice  
treated  with  HCQ  and  mice  treated  with  HCQ  alone.  Fetal  resorption  frequency  
(FRF)  was  calculated  as  the  number  of  resorptions  divided  by  the  total  number  of  
resorptions  plus  viable  fetuses.  N=6-­7  /  experimental  group.  *  different  from  NHIgG,  
p<0.05  
  
Table  3.  In  vivo  1HMRS  studies  in  placenta  and  fetal  brain.      
Values  of  different  different  metabolic  peaks  in  placentas  and  fetal  brains  of  APS-­  
mice  with  and  without  HCQ  treatment  and  control  mice  treated  with  NHIgG  at  day  15  
of  pregnancy.  The  1HMRS  signal  from  creatine  (Cr,  measure  of  the  global  brain  or  
placental  function  or  integrity)  was  used  to  normalize  the  signals  from  metabolites  
measured  within  the  same  voxel.  N=5-­6  /  experimental  group.  Glucose  =  Glc,  lactate  
=  Lac,    glycerophosphocholine  =GPC,  phosphocholine  =PCh.  *  different  from  
NHIgG,  p<0.05  
  
Table  4.  Ex-­vivo  gamma  counting  showing  the  biodistribution  of  NHIgG  and  aβ2GPI  
in  pregnant  and  nonpregnant  mice.  Results  are  expressed  as  amount  of  IgG  per  g  of  
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tissue  (ng  IgG/  g  of  tissue)  N=4-­5  mice/group.  *  different  from  NHIgG,  p<0.05,    #  
different  from  pregnant  mice,  p<0.05  
  
Table  5.  Effect  of  HCQ  on  antibody  complement  C1q  fixation  and  C3  activation  
capacity.    Values  of  C1q  fixation  and  C3b/iC3b/C3  generation  are  expressed  as  O.D.  
at  wavelength  (λ)  =  450.  Complement  fixing  mouse  monoclonal  aPL  antibody  FB1  
and  control  non  fixing  FD1  antibody  were  used  in  the  ELISA.  N=5-­7  /  experimental  
group.*  different  from  control  antibody  FD1,  p<0.05;;  #  different  from  complement  
fixing  antibody  FB1,  p<0.05.  
  
Table  6.  HCQ  inhibits  complement  activation  in  vivo.    
Complement  split  products  C3adesArg  and  C5adesArg  in  serum  from  NHIgG-­treated  
mice,  APS-­mice  and  APS-­mice  treated  with  HCQ.  N=5-­6  mice/experimental  group.  
*Different  from  NHIgG,  p<0.05  
  
Table  7.  C5adesArg  levels  and  antiβ2-­GPI  titres  in  patients  before  and  after  (>60  
days)  treatment  with  HCQ  (6.5  mg/kg/day).  *  different  from  before  HCQ,  p<0.05  
  
Figure  1.    Protective  effects  of  HCQ  in  pregnant  treated  with  aβ2GPI  antibodies  
A-­  Uteri  harvested  at  day  15  of  pregnancy.  There  were  increased  number  of  
resorptions  (asterisks)  in  the  utero  of  APS-­mice  compared  to  control  mice  treated  
with  NHIgG  and  APS-­  mice  treated  with  HCQ.  Data  are  representative  of  
observations  in  5–6  mice  per  group.  
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B-­  Increased  superoxide  production  (DHE,  red  staining)  in  APS-­mice  compared  to  
NHIgG-­treated  mice.  HCQ  treatment  prevented  increased  superoxide  production  
induced  by  aβ2GPI  antibodies  (n=5-­6  mice  per  group).  
C-­  Microscope  photomicrographs  demonstrating  decreased  NF-­200  and  MAP-­2  
staining  (green  fluorescence)  in  the  fetal  brains  from  APS-­mice  compared  to  NHIgG  
control  group.  HCQ  treatment  prevented  abnormal  cortical  brain  development  and  
increased  NF-­200  and  MAP-­2  staining.  Diamidino-­2-­phenylindole  (DAPI)  was  used  
for  nuclear  counterstain  in  immunofluorescence  studies  in  C  and  D.  




Figure  2:  NanoSPECT/CT  images  of  indium111-­labelled  aβ2GPI  and  NHIgG    
A-­  Non  pregnant  mouse  injected  with  aβ2GPI  (left)  and  NHIgG  (right)  
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B-­  Pregnant  mouse  injected  with  aβ2GPI  (left)  and  NHIgG  (right)  
B1-­  SPECT/CT  of  isolated  utero  from  a  mouse  injected  with  In111-­aβ2GPI  
B2-­  SPECT/CT  of  isolated  utero  from  a  mouse  injected  with  In111-­NHIgG  
  
Figure  3.  Immunohistochemical  studies  to  detect  deposition  of  aβ2GPI  and  NHIgG  
in  placenta  and  fetal  brain.  Expression  of  β2GPI  protein  in  placenta  and  fetal  brain  in  
control  mice.  aβ2GPI  and  NHIgG  deposition  in  mouse  tissue  (placenta  and  fetal  
cortical  brain)  was  detected  using  an  antihuman  IgG  antibody  labelled  with  Texas  
Red.    
A-­  detection  of  aβ2GPI  in  the  placenta  from  mouse  injected  aβ2GPI.  B-­  Detection  of  
aβ2GPI  in  fetal  cortical  brain  from  a  mouse  injected  with  aβ2GPI.  C-­  Detection  of  
NHIgG  in  the  placenta  from  a  mouse  injected  with  NHIgG.  D-­  Detection  of  NHIgG  in  
the  fetal  cortical  brain  in  a  mouse  injected  with  NHIgG.    
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Expression  of  β2GPI  in  placenta  (E)  and  fetal  brain  (F)  was  detected  with  FITC-­
conjugated  antibodies  (green  fluorescence).  Diamidino-­2-­phenylindole  (DAPI)  was  
used  for  nuclear  counterstains  in  all  immunofluorescence  studies.  Data  are  
representative  of  observations  in  5–6  mice  per  group.  10  views  per  slide  were  
analyzed  in  each  experimental  condition.  
  
  
Figure  4.  HCQ  does  not  affect  aβ2GPI  antibodies  binding    
A-­  Deposition  of  aβ2GPI  antibodies  (red  fluorescence)  in  placenta  and  fetal  brain  in  
APS-­mice  and  APS-­mice  treated  with  HCQ.  
B-­  C3  deposition  (green  fluorescence)  in  placentas  and  fetal  brains  from  APS-­mice  
and  APS-­mice  treated  with  HCQ.  C3  deposition  was  attenuated  by  HCQ  treatment  
both  in  placentas  and  fetal  brains  at  d15  of  pregnancy  in  APS-­mice.    
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Diamidino-­2-­phenylindole  (DAPI)  was  used  for  nuclear  counterstains  in  all  




Supplementary  file  for  online  publication.  Video  showing  nanoSPECT/CT  images  of  
indium111-­labelled  aβ2GPI  and  NHIgG  in  pregnant  and  non  pregnant  mice.  
  
